Amcenestrant - Sanofi
Alternative Names: SAR 439859; SERD '859Latest Information Update: 24 Jan 2025
At a glance
- Originator Sanofi
- Developer Alliance Foundation Trials; Breast International Group; European Organisation for Research and Treatment of Cancer; Sanofi
- Class 2 ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Chlorobenzenes; Ethers; Fluorinated hydrocarbons; Phenols; Pyrrolidines; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 26 Dec 2024 Sanofi terminates Phase-I clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Japan (PO) due to sponsors decision to end the study prematurely (NCT03816839)
- 08 Nov 2024 Sanofi terminates phase-I/II AMEERA-1 trial in Breast cancer (Late-stage disease, Second-line therapy or greater, Monotherapy, Metastatic disease, Combination therapy) in Canada, Belgium, Czechia, Italy, Poland, Portugal, Spain, France, USA and United Kingdom (PO) (NCT03284957),
- 19 Oct 2022 Adverse events and efficacy data from a phase II AMEERA-3 trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO 2022)